These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
163 related articles for article (PubMed ID: 7909829)
1. TCR V beta 3+ and V beta 6+ CTL recognize tumor-associated antigens related to HER2/neu expression in HLA-A2+ ovarian cancers. Peoples GE; Yoshino I; Douville CC; Andrews JV; Goedegebuure PS; Eberlein TJ J Immunol; 1994 May; 152(10):4993-9. PubMed ID: 7909829 [TBL] [Abstract][Full Text] [Related]
2. Association of HER2/neu expression with sensitivity to tumor-specific CTL in human ovarian cancer. Yoshino I; Peoples GE; Goedegebuure PS; Maziarz R; Eberlein TJ J Immunol; 1994 Mar; 152(5):2393-400. PubMed ID: 8133050 [TBL] [Abstract][Full Text] [Related]
3. The HER2/neu-derived peptide p654-662 is a tumor-associated antigen in human pancreatic cancer recognized by cytotoxic T lymphocytes. Peiper M; Goedegebuure PS; Linehan DC; Ganguly E; Douville CC; Eberlein TJ Eur J Immunol; 1997 May; 27(5):1115-23. PubMed ID: 9174600 [TBL] [Abstract][Full Text] [Related]
4. HER2/neu-derived peptides are shared antigens among human non-small cell lung cancer and ovarian cancer. Yoshino I; Goedegebuure PS; Peoples GE; Parikh AS; DiMaio JM; Lyerly HK; Gazdar AF; Eberlein TJ Cancer Res; 1994 Jul; 54(13):3387-90. PubMed ID: 7912166 [TBL] [Abstract][Full Text] [Related]
5. Pancreatic cancer associated ascites-derived CTL recognize a nine-amino-acid peptide GP2 derived from HER2/neu. Peiper M; Goedegebuure PS; Izbicki JR; Eberlein TJ Anticancer Res; 1999; 19(4A):2471-5. PubMed ID: 10470176 [TBL] [Abstract][Full Text] [Related]
6. Tumor-specific and HLA-A2-restricted cytolysis by tumor-associated lymphocytes in human metastatic breast cancer. Linehan DC; Goedegebuure PS; Peoples GE; Rogers SO; Eberlein TJ J Immunol; 1995 Nov; 155(9):4486-91. PubMed ID: 7594611 [TBL] [Abstract][Full Text] [Related]
8. T cell receptor V beta 2 and V beta 6 mediate tumor-specific cytotoxicity by tumor-infiltrating lymphocytes in ovarian cancer. Peoples GE; Davey MP; Goedegebuure PS; Schoof DD; Eberlein TJ J Immunol; 1993 Nov; 151(10):5472-80. PubMed ID: 8228239 [TBL] [Abstract][Full Text] [Related]
9. Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes. Brossart P; Stuhler G; Flad T; Stevanovic S; Rammensee HG; Kanz L; Brugger W Cancer Res; 1998 Feb; 58(4):732-6. PubMed ID: 9485028 [TBL] [Abstract][Full Text] [Related]
10. Simultaneous production of T helper-1-like cytokines and cytolytic activity by tumor-specific T cells in ovarian and breast cancer. Goedegebuure PS; Douville CC; Doherty JM; Linehan DC; Lee KY; Ganguly EK; Eberlein TJ Cell Immunol; 1997 Feb; 175(2):150-6. PubMed ID: 9023420 [TBL] [Abstract][Full Text] [Related]
11. MHC-restricted recognition of autologous melanoma by tumor-specific cytotoxic T cells. Evidence for restriction by a dominant HLA-A allele. Crowley NJ; Darrow TL; Quinn-Allen MA; Seigler HF J Immunol; 1991 Mar; 146(5):1692-9. PubMed ID: 1671580 [TBL] [Abstract][Full Text] [Related]
12. Shared human melanoma antigens. Recognition by tumor-infiltrating lymphocytes in HLA-A2.1-transfected melanomas. Kawakami Y; Zakut R; Topalian SL; Stötter H; Rosenberg SA J Immunol; 1992 Jan; 148(2):638-43. PubMed ID: 1729379 [TBL] [Abstract][Full Text] [Related]
14. Cytotoxic T cells isolated from ovarian malignant ascites recognize a peptide derived from the HER-2/neu proto-oncogene. Ioannides CG; Fisk B; Fan D; Biddison WE; Wharton JT; O'Brian CA Cell Immunol; 1993 Oct; 151(1):225-34. PubMed ID: 7691418 [TBL] [Abstract][Full Text] [Related]
15. Dual recognition of a human cytotoxic T-cell clone for melanoma antigens. Kubo H; Abe J; Obata F; Nakajima H; Tsunoda M; Ogawa A; Nakayama S; Beck Y; Kohsaka T; Darrow TL; Abdel-Wahab Z; Saida T; Takiguchi M Cancer Res; 1996 May; 56(10):2368-74. PubMed ID: 8625313 [TBL] [Abstract][Full Text] [Related]
16. The role of HLA class I antigens in recognition of melanoma cells by tumor-specific cytotoxic T lymphocytes. Evidence for shared tumor antigens. Darrow TL; Slingluff CL; Seigler HF J Immunol; 1989 May; 142(9):3329-35. PubMed ID: 2785141 [TBL] [Abstract][Full Text] [Related]
17. Oligopeptide induction of a cytotoxic T lymphocyte response to HER-2/neu proto-oncogene in vitro. Fisk B; Chesak B; Pollack MS; Wharton JT; Ioannides CG Cell Immunol; 1994 Sep; 157(2):415-27. PubMed ID: 7915203 [TBL] [Abstract][Full Text] [Related]
18. Analysis of MAGE-3-specific cytolytic T lymphocytes in human leukocyte antigen-A2 melanoma patients. Valmori D; Liénard D; Waanders G; Rimoldi D; Cerottini JC; Romero P Cancer Res; 1997 Feb; 57(4):735-41. PubMed ID: 9044853 [TBL] [Abstract][Full Text] [Related]
19. T cell receptor (TCR) structure of autologous melanoma-reactive cytotoxic T lymphocyte (CTL) clones: tumor-infiltrating lymphocytes overexpress in vivo the TCR beta chain sequence used by an HLA-A2-restricted and melanocyte-lineage-specific CTL clone. Sensi M; Salvi S; Castelli C; Maccalli C; Mazzocchi A; Mortarini R; Nicolini G; Herlyn M; Parmiani G; Anichini A J Exp Med; 1993 Oct; 178(4):1231-46. PubMed ID: 8376931 [TBL] [Abstract][Full Text] [Related]
20. Identification of MART-1-specific T-cell receptors: T cells utilizing distinct T-cell receptor variable and joining regions recognize the same tumor epitope. Cole DJ; Weil DP; Shamamian P; Rivoltini L; Kawakami Y; Topalian S; Jennings C; Eliyahu S; Rosenberg SA; Nishimura MI Cancer Res; 1994 Oct; 54(20):5265-8. PubMed ID: 7522957 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]